Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Anticoagulation therapy

Idrabiotaparinux noninferior to warfarin for long-term treatment of pulmonary embolism

Nature Reviews Cardiology volume 9, page 68 (2012)Cite this article

Subjects

Access through your institution
Buy or subscribe

Patients with pulmonary embolism are currently treated with a low-molecular-weight heparin (such as enoxaparin) and an antagonist of vitamin K (for example, warfarin); however, “warfarin requires lab testing, dose monitoring, and adjustment for interactions with foods and alcohol,” highlights Professor Harry Büller from the Academic Medical Center in Amsterdam.

Professor Büller and colleagues randomly allocated 3,202 patients with acute pulmonary embolism from 37 countries to receive subcutaneous enoxaparin (1.0 mg/kg) twice daily for 5–10 days and then either conventional, dose-adjusted warfarin tablets (target international normalized ratio 2–3) or subcutaneous idrabiotaparinux (starting dose 3.0 mg). A double-dummy, double-blind trial design was used and regimen duration was 3–6 months.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Büller, H. R. et al. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet doi:10.1016/S0140-6736(11)61505-5

    Article  Google Scholar 

Download references

Authors
  1. Gregory B. Lim
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lim, G. Idrabiotaparinux noninferior to warfarin for long-term treatment of pulmonary embolism. Nat Rev Cardiol 9, 68 (2012). https://doi.org/10.1038/nrcardio.2011.201

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrcardio.2011.201

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing